Chief Medical Officer Warns Against Sole Reliance on Weight-Loss Drugs
Weight-loss drugs cannot single-handedly resolve the UK's escalating obesity crisis and may cause unpleasant side-effects for many users, the government’s chief medical officer has cautioned.
Prof Chris Whitty delivered a comprehensive critique of these drugs during a speech in London on Thursday evening.
“Just relying on the drugs seems to me the wrong answer,”he stated.
His cautious stance on medications such as Mounjaro and Wegovy, which are classified as GLP-1 agonists, contrasts with the more optimistic approach of the health secretary in addressing obesity.
Giving the annual Medical Journalists Association lecture, Whitty emphasized the risks of overdependence on these drugs for obesity treatment. He advocated for stronger measures to restrict junk food advertising and to improve the nutritional quality of food as more effective strategies to prevent obesity.
“Does anyone in this group believe that the correct answer is to allow obesity to rise because of pretty aggressive marketing of obesogenic foods to children and then stick them on GLP-1 agonists at the age of 18? I think it is shocking if that is where we end up.
Really, is our answer to say ‘give up on public health’, which we know will work, in children and then just rely on drugs to get us out of a hole? I do not think this is a socially acceptable answer. Actually, I do not think that’s a medically acceptable answer, because these drugs are not benign,”Whitty said.
“GLP-1s, they are very good drugs. [But] we know that if you stop them, weight is regained. Some people have very bad reactions to them. It’s very small numbers, but they do. And a large number of people have unpleasant side-effects, largely gastrointestinal,”he added.
GLP-1 agonists, sometimes referred to as “fat jabs,” have been linked to increased risks of complications such as gallbladder disease, pancreatitis, and thyroid cancer among women using contraception.
With weight often regained after discontinuing GLP-1s, patients could face a future with reduced muscle mass and increased fat compared to their pre-treatment state, Whitty warned.
Decades of UK policy aimed at reducing obesity have largely failed, in contrast to the success seen in other countries, which demonstrates that effective intervention is possible, he said. Whitty expressed concern that obesity rates are worsening, unlike the progress made in campaigns against smoking and air pollution.
“In obesity, things are going the wrong way. They don’t have to. In France, for example, levels of obesity are pretty well the same now as they were in 1990. No one can claim the French don’t like their food,”he remarked.
Asked whether ministers should encourage or compel food manufacturers to improve the healthiness of their products, Whitty affirmed that
“reformulation definitely has a part to play in this”and urged reductions in sugar and fat content.
He also highlighted that industries facing potential regulation deploy powerful lobbyists to influence media narratives, which in turn discourage ministers from implementing bold public health policies. The media often frame such policies as “nanny state” interventions, despite public support for action.
Obesity Experts Support Whitty’s Call for Stronger Food Policies
Obesity experts have welcomed Whitty’s remarks.
Sonia Pombo, head of research and impact at Action on Salt and Sugar, stated:
“Weight loss drugs are not, and must never be treated as, a substitute for a strong, effective food policy. Depending on GLP-1s to counter the harms of an unhealthy food environment is simply putting a plaster on a system that continues to generate ill-health.”
Katherine Jenner, director of the Obesity Health Alliance, added:
“It is not a common-sense approach for the government to continue to let children grow up in environments flooded with unhealthy options, only to rely on medicines later in life to address the harm. We should not accept a system where the food industry drives obesity and the pharmaceutical industry is left to pick up the pieces.
Childhood obesity is preventable. Stronger action, from reformulating food and restricting junk food advertising aimed at children to setting targets for companies to reduce sales of unhealthy processed products, can help create healthier environments and better outcomes. The UK should be guided by the evidence and act far more boldly to prevent obesity before it starts.”
